Cancer genomics: technology, discovery, and translation

Ben Tran, Janet E. Dancey, Suzanne Kamel-Reid, John Douglas Mcpherson, Philippe L. Bedard, Andrew M K Brown, Tong Zhang, Patricia Shaw, Nicole Onetto, Lincoln Stein, Thomas J. Hudson, Benjamin G. Neel, Lillian L. Siu

Research output: Contribution to journalReview article

122 Citations (Scopus)

Abstract

In recent years, the increasing awareness that somatic mutations and other genetic aberrations drive human malignancies has led us within reach of personalized cancer medicine (PCM). The implementation of PCM is based on the following premises: genetic aberrations exist in human malignancies; a subset of these aberrations drive oncogenesis and tumor biology; these aberrations are actionable (defined as having the potential to affect management recommendations based on diagnostic, prognostic, and/or predictive implications); and there are highly specific anticancer agents available that effectively modulate these targets. This article highlights the technology underlying cancer genomics and examines the early results of genome sequencing and the challenges met in the discovery of new genetic aberrations. Finally, drawing from experiences gained in a feasibility study of somatic mutation genotyping and targeted exome sequencing led by Princess Margaret Hospital-University Health Network and the Ontario Institute for Cancer Research, the processes, challenges, and issues involved in the translation of cancer genomics to the clinic are discussed.

Original languageEnglish (US)
Pages (from-to)647-660
Number of pages14
JournalJournal of Clinical Oncology
Volume30
Issue number6
DOIs
StatePublished - Feb 20 2012
Externally publishedYes

Fingerprint

Genomics
Technology
Neoplasms
Precision Medicine
Exome
Mutation
Feasibility Studies
Ontario
Antineoplastic Agents
Carcinogenesis
Genome
Health

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Tran, B., Dancey, J. E., Kamel-Reid, S., Mcpherson, J. D., Bedard, P. L., Brown, A. M. K., ... Siu, L. L. (2012). Cancer genomics: technology, discovery, and translation. Journal of Clinical Oncology, 30(6), 647-660. https://doi.org/10.1200/JCO.2011.39.2316

Cancer genomics : technology, discovery, and translation. / Tran, Ben; Dancey, Janet E.; Kamel-Reid, Suzanne; Mcpherson, John Douglas; Bedard, Philippe L.; Brown, Andrew M K; Zhang, Tong; Shaw, Patricia; Onetto, Nicole; Stein, Lincoln; Hudson, Thomas J.; Neel, Benjamin G.; Siu, Lillian L.

In: Journal of Clinical Oncology, Vol. 30, No. 6, 20.02.2012, p. 647-660.

Research output: Contribution to journalReview article

Tran, B, Dancey, JE, Kamel-Reid, S, Mcpherson, JD, Bedard, PL, Brown, AMK, Zhang, T, Shaw, P, Onetto, N, Stein, L, Hudson, TJ, Neel, BG & Siu, LL 2012, 'Cancer genomics: technology, discovery, and translation', Journal of Clinical Oncology, vol. 30, no. 6, pp. 647-660. https://doi.org/10.1200/JCO.2011.39.2316
Tran B, Dancey JE, Kamel-Reid S, Mcpherson JD, Bedard PL, Brown AMK et al. Cancer genomics: technology, discovery, and translation. Journal of Clinical Oncology. 2012 Feb 20;30(6):647-660. https://doi.org/10.1200/JCO.2011.39.2316
Tran, Ben ; Dancey, Janet E. ; Kamel-Reid, Suzanne ; Mcpherson, John Douglas ; Bedard, Philippe L. ; Brown, Andrew M K ; Zhang, Tong ; Shaw, Patricia ; Onetto, Nicole ; Stein, Lincoln ; Hudson, Thomas J. ; Neel, Benjamin G. ; Siu, Lillian L. / Cancer genomics : technology, discovery, and translation. In: Journal of Clinical Oncology. 2012 ; Vol. 30, No. 6. pp. 647-660.
@article{0635e774be394d13854ef5f0fa920a47,
title = "Cancer genomics: technology, discovery, and translation",
abstract = "In recent years, the increasing awareness that somatic mutations and other genetic aberrations drive human malignancies has led us within reach of personalized cancer medicine (PCM). The implementation of PCM is based on the following premises: genetic aberrations exist in human malignancies; a subset of these aberrations drive oncogenesis and tumor biology; these aberrations are actionable (defined as having the potential to affect management recommendations based on diagnostic, prognostic, and/or predictive implications); and there are highly specific anticancer agents available that effectively modulate these targets. This article highlights the technology underlying cancer genomics and examines the early results of genome sequencing and the challenges met in the discovery of new genetic aberrations. Finally, drawing from experiences gained in a feasibility study of somatic mutation genotyping and targeted exome sequencing led by Princess Margaret Hospital-University Health Network and the Ontario Institute for Cancer Research, the processes, challenges, and issues involved in the translation of cancer genomics to the clinic are discussed.",
author = "Ben Tran and Dancey, {Janet E.} and Suzanne Kamel-Reid and Mcpherson, {John Douglas} and Bedard, {Philippe L.} and Brown, {Andrew M K} and Tong Zhang and Patricia Shaw and Nicole Onetto and Lincoln Stein and Hudson, {Thomas J.} and Neel, {Benjamin G.} and Siu, {Lillian L.}",
year = "2012",
month = "2",
day = "20",
doi = "10.1200/JCO.2011.39.2316",
language = "English (US)",
volume = "30",
pages = "647--660",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "6",

}

TY - JOUR

T1 - Cancer genomics

T2 - technology, discovery, and translation

AU - Tran, Ben

AU - Dancey, Janet E.

AU - Kamel-Reid, Suzanne

AU - Mcpherson, John Douglas

AU - Bedard, Philippe L.

AU - Brown, Andrew M K

AU - Zhang, Tong

AU - Shaw, Patricia

AU - Onetto, Nicole

AU - Stein, Lincoln

AU - Hudson, Thomas J.

AU - Neel, Benjamin G.

AU - Siu, Lillian L.

PY - 2012/2/20

Y1 - 2012/2/20

N2 - In recent years, the increasing awareness that somatic mutations and other genetic aberrations drive human malignancies has led us within reach of personalized cancer medicine (PCM). The implementation of PCM is based on the following premises: genetic aberrations exist in human malignancies; a subset of these aberrations drive oncogenesis and tumor biology; these aberrations are actionable (defined as having the potential to affect management recommendations based on diagnostic, prognostic, and/or predictive implications); and there are highly specific anticancer agents available that effectively modulate these targets. This article highlights the technology underlying cancer genomics and examines the early results of genome sequencing and the challenges met in the discovery of new genetic aberrations. Finally, drawing from experiences gained in a feasibility study of somatic mutation genotyping and targeted exome sequencing led by Princess Margaret Hospital-University Health Network and the Ontario Institute for Cancer Research, the processes, challenges, and issues involved in the translation of cancer genomics to the clinic are discussed.

AB - In recent years, the increasing awareness that somatic mutations and other genetic aberrations drive human malignancies has led us within reach of personalized cancer medicine (PCM). The implementation of PCM is based on the following premises: genetic aberrations exist in human malignancies; a subset of these aberrations drive oncogenesis and tumor biology; these aberrations are actionable (defined as having the potential to affect management recommendations based on diagnostic, prognostic, and/or predictive implications); and there are highly specific anticancer agents available that effectively modulate these targets. This article highlights the technology underlying cancer genomics and examines the early results of genome sequencing and the challenges met in the discovery of new genetic aberrations. Finally, drawing from experiences gained in a feasibility study of somatic mutation genotyping and targeted exome sequencing led by Princess Margaret Hospital-University Health Network and the Ontario Institute for Cancer Research, the processes, challenges, and issues involved in the translation of cancer genomics to the clinic are discussed.

UR - http://www.scopus.com/inward/record.url?scp=84863393678&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863393678&partnerID=8YFLogxK

U2 - 10.1200/JCO.2011.39.2316

DO - 10.1200/JCO.2011.39.2316

M3 - Review article

C2 - 22271477

AN - SCOPUS:84863393678

VL - 30

SP - 647

EP - 660

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 6

ER -